Novel Agents for Preventing and Treating Disorders Connected to Impaired Neurotransmission
申请人:De Saizieu Antoine
公开号:US20070293563A1
公开(公告)日:2007-12-20
The present invention refers to coumarin ethers of the formula (I), wherein R
1
is H, OH or (E)-3-methyl-but-2-enyl, R
2
is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z, E/Z)-1-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R
3
is H, R
1
and R
2
O together for the group —O—C(C(═CH
2
)CH
3
)H—CH
2
—O— or the group —C(H)═C(H)—C(CH
3
)
2
—O— or R
2
O and R
3
together form the group —O—C(H)(C(CH
3
)
2
(H)—O—C(O)CH
3
)—CH
2
—, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.